TG4050 harnesses Transgene’s myvac platform and NEC’s AI-powered neoantigen prediction technology to tailor vaccines to each patient’s tumor
The acquisition aims to bolster Merck’s hematology portfolio with Terns’ lead oncology candidate, TERN-701
Board approves allotment of shares to promoter Shankar Varadharajan following warrant conversion under SEBI Regulation 30 disclosure
The deal gives Cupid immediate access to Style Baazar’s fast-growing network of over 260 stores
As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions
Lonza will take on technology transfer, process optimization, and cGMP manufacturing, leveraging its global network and expertise in highly potent compounds
Pfizer recommends that shareholders do not tender their shares in response to Tutanota’s offer
Dr Severin Schwan was re-elected as Chairman of the Board with 97.75% of the votes
Asahi Kasei is consistently pursuing its strategy of building a focused, sustainable specialty pharmaceutical platform for immunocompromised and medically complex patient groups
Subscribe To Our Newsletter & Stay Updated
